KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables (2018 - 2025)

Adaptive Biotechnologies' Receivables history spans 8 years, with the latest figure at $51.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 20.53% year-over-year to $51.9 million; the TTM value through Dec 2025 reached $51.9 million, up 20.53%, while the annual FY2025 figure was $51.9 million, 20.53% up from the prior year.
  • Receivables for Q4 2025 was $51.9 million at Adaptive Biotechnologies, up from $46.3 million in the prior quarter.
  • Across five years, Receivables topped out at $51.9 million in Q4 2025 and bottomed at $16.5 million in Q2 2021.
  • The 5-year median for Receivables is $34.6 million (2023), against an average of $34.2 million.
  • The largest annual shift saw Receivables surged 117.22% in 2022 before it dropped 4.62% in 2023.
  • A 5-year view of Receivables shows it stood at $18.8 million in 2021, then soared by 117.22% to $40.9 million in 2022, then decreased by 4.62% to $39.0 million in 2023, then grew by 10.42% to $43.0 million in 2024, then rose by 20.53% to $51.9 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Receivables are $51.9 million (Q4 2025), $46.3 million (Q3 2025), and $45.6 million (Q2 2025).